Big Pharma’s Play in the Marijuana Arena: Insys, Synthetic THC, and the Fight Over Legalization
When voters in several states approved recreational marijuana in November 2016, Arizona stood out as the lone hold‑out. The defeat of the state’s cannabis measure was backed by a substantial financial contribution from Insys Therapeutics, a pharmaceutical company that donated $500,000 to the anti‑legalization campaign—one of the largest single contributions ever recorded for a marijuana opposition effort.
To many activists, Insys’s motive appeared clear: suppress a competing product that could erode its own market share. Those suspicions were reinforced months later when the U.S. Drug Enforcement Administration (DEA) granted Insys approval to develop Syndros, a synthetic liquid form of tetrahydrocannabinol (THC) intended for chemotherapy‑induced nausea and AIDS‑related anorexia.
From Opposition to Approval
Syndros differs from illicit street synthetics such as K2 or Spice, which are often made by spraying unknown chemicals onto plant material and have been linked to overdoses and deaths. Instead, Syndros is a purified, lab‑produced THC formulation that has undergone the FDA’s regulatory pathway.
The approval triggered a sharp backlash from cannabis advocates. Dr. Gina Berman, medical director of the Giving Tree Wellness Center dispensary in Phoenix, remarked, “It’s a little bit disgusting when you think of the collateral damage for human beings,” noting that Insys had helped block a natural treatment that it now seeks to market in a synthetic form.
Fentanyl Ties and Market Concerns
Insys also manufactures fentanyl, a synthetic opioid up to 50 times more potent than heroin. In December 2016, six former Insys executives were arrested on charges of bribing doctors to prescribe fentanyl to patients who did not need it—a case that underscores the company’s involvement in the opioid crisis.
Critics argue that Insys’s efforts to impede regulated marijuana use are especially troubling given fentanyl’s role in rising opioid deaths. W. David Bradford, a professor at the University of Georgia whose research shows medical marijuana reduces prescription drug use, stated, “There’s conclusive evidence that marijuana is effective for pain management. And nobody has ever died from inhaled cannabis use.”
Implications for Small Operators
Small dispensaries often operate as “mom‑and‑pop” shops lacking the lobbying power, legal teams, and financial resources of large pharmaceutical firms. As JP Holyoak, an Arizona dispensary owner and former chairman of the state’s legalization campaign, observed, “They recognize that the horse has left the barn regarding marijuana. They can’t beat it, so now they’re trying to just take it over.”
Industry analysts note that the current legal gray area—where cannabis remains illegal federally but is permitted in many states—creates hurdles such as banking restrictions and uneven law enforcement. These obstacles disproportionately affect small growers, while companies with the infrastructure to navigate FDA approvals, like Insys, can potentially capture a share of the emerging market.
Looking Ahead
Some experts, such as Michael Collins of the Drug Policy Alliance, believe that pharmaceutical companies will not directly interfere with the growing recreational market, which remains distinct from traditional drug markets. Nevertheless, the trend of big‑pharma investment in synthetic cannabinoids raises questions about future market consolidation, potential acquisitions of dispensaries, and the broader implications for patients seeking affordable, plant‑based therapies.
Source: Here
